| Not Yet Recruiting | Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treat NCT07463807 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Not Yet Recruiting | ²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor St NCT04579523 | Fred Hutchinson Cancer Center | Phase 1 |
| Not Yet Recruiting | Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatm NCT06948084 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Selvigaltin With Standard of Care Treatment for the Treatment of Relapsed/Refractory Multiple Myeloma NCT07082270 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relap NCT07181941 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Recruiting | CRISPR Delivered Anti-BCMA Car-T Therapy for Relapsed or Refractory Multiple Myeloma NCT07340853 | Thomas Martin, MD | Phase 1 |
| Recruiting | Prehabilitation With Aerobic and Resistance Exercise for Improving Physical Fitness and Quality of Life Outcom NCT07045727 | Mayo Clinic | N/A |
| Recruiting | Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple NCT06940297 | Mayo Clinic | Phase 2 |
| Recruiting | Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Pa NCT06627751 | Roswell Park Cancer Institute | Phase 2 |
| Recruiting | Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractor NCT06232044 | Alliance for Clinical Trials in Oncology | Phase 1 / Phase 2 |
| Recruiting | SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed NCT06622005 | Roswell Park Cancer Institute | Phase 1 |
| Recruiting | Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma NCT06785415 | Mayo Clinic | Phase 1 / Phase 2 |
| Terminated | ST-067 and Teclistamab for the Treatment of Relapsed or Refractory Multiple Myeloma NCT06588660 | University of Washington | Phase 1 |
| Recruiting | Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma NCT06465316 | National Cancer Institute (NCI) | Phase 1 |
| Withdrawn | CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma NCT05950113 | Jonsson Comprehensive Cancer Center | Phase 1 |
| Active Not Recruiting | Donor Immune Cells (TGFbi NK Cells) and Isatuximab for the Treatment of Relapsed or Refractory Multiple Myelom NCT06203912 | Elvira Umyarova | Phase 1 |
| Recruiting | Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple NCT05847569 | Mayo Clinic | Phase 2 |
| Recruiting | Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BC NCT05981209 | Abdullah Khan | Phase 1 |
| Active Not Recruiting | Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple NCT04883242 | University of Washington | Phase 2 |
| Active Not Recruiting | Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With Rela NCT04764942 | Mayo Clinic | Phase 1 / Phase 2 |
| Completed | Ixazomib and Pevonedistat in Treating Patients With Multiple Myeloma That Has Come Back or Does Not Respond to NCT03770260 | National Cancer Institute (NCI) | Phase 1 |
| Active Not Recruiting | CB-839 HCl in Combination With Carfilzomib and Dexamethasone in Treating Patients With Recurrent or Refractory NCT03798678 | National Cancer Institute (NCI) | Phase 1 |
| Terminated | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma NCT03031730 | National Cancer Institute (NCI) | Phase 1 |
| Unknown | Safety, Pharmacokinetics and Efficacy Study of Bisthianostat in Refractory or Recurrent Multiple Myeloma Patie NCT03618602 | Shanghai Theorion Pharmaceutical Co Ltd. | Phase 1 |
| Active Not Recruiting | High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Rel NCT03389347 | University of Washington | N/A |
| Active Not Recruiting | Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymph NCT02465060 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Wild-Type Reovirus in Combination With Carfilzomib and Dexamethasone in Treating Patients With Relapsed or Ref NCT02101944 | National Cancer Institute (NCI) | Phase 1 |